Sinusitis
Conditions
Brief summary
Healthy children may develop symptoms of chronic sinusitis such as chronic cough, chronic runny nose, nasal congestion, even headaches. Such symptoms may persist long after the child gets over other symptoms of a cold and commonly result in the prescription of oral antibiotics. The purpose of this study is to evaluate whether using saline alone or saline plus an antibiotic (gentamycin) to irrigate the nose directly once a day for 6 weeks is effective and safe for the treatment of the above named symptoms. Computerized axial tomography (CAT) scans and quality of life surveys will be used to compare the health of the sinuses before and after treatment, and scored to determine which of the two treatments, saline alone or saline with gentamycin, is more effective in the treatment of this condition. The study hypothesis is that intranasal saline irrigation will work as well as saline plus gentamycin, and that majority of the patients will experience significant improvement after a 6 week treatment period.
Detailed description
In the pediatric population, rhinosinusitis is a common concern resulting frequently in the frequent and unsuccessful prescription of systemic oral antibiotic therapy. Children typically experience an estimated 6-8 upper respiratory illnesses per year, usually viral, and only 13% are estimated to result in true sinusitis. True and chronic sinusitis, if not adequately treated, may result in long term symptoms including nasal airway obstruction, nasal congestion, persistent mucopurulent rhinorrhea, daytime and nocturnal cough, headaches, daytime fatigue, and even exacerbation or poor control of underlying asthma. A child's quality of life can be severely impacted as is their caretaker's due to days of missed school, frequency of doctor visits and courses of oral antibiotic therapy prescribed for the above mentioned symptoms, which ultimately result in the development of resistant organisms in addition to potential negative side effects associated with systemic oral antibiotic use. Intranasal saline irrigation is underutilized in the pediatric population, most likely due to the presumption that children will not cooperate nor tolerate the act of irrigation. Saline irrigation of the nose is an inexpensive and generally well tolerated treatment with very little side effects or risks. Rigorous data regarding the efficacy of saline irrigation has become more available in this past decade, with most studies demonstrating a clear improvement in patient quality of life as measured by various study instruments or outcome surveys. In our protocol, patients will be randomized to receive either saline alone or saline plus gentamycin in the solution form for nasal irrigation once daily for a six week treatment period. Weekly phone calls will be made to check for possible adverse events while patients are on treatment, and at the end of the treatment period another CAT scan will be performed to assess the status of the sinuses. Overall improvement will be determined based on the sinus status on the second CAT scan as well as the quality of life survey filled out by parents.
Interventions
Intranasal Saline
Intranasal irrigation
Sponsors
Study design
Eligibility
Inclusion criteria
* Healthy children age 4-17 * History of Recurrent or Chronic Sinusitis * Definition: History must include \> 3 months of any or a combination of the following symptoms: * Nasal congestion/nasal airway obstruction * Rhinorrhea/Nasal discharge * Persistent cough (daytime) * Postnasal drip * Headache * Facial pain * Foul breath * Intermittent fever * Caregiver (proxy responsible) able to read and understand English * Has had at least 3 courses or a total of 21 days of oral antibiotic therapy for above symptoms in the previous 3 months * Child has a CT scan of the coronal sinus without contrast within two months prior to visit date, which demonstrates and opacification of a single or multiple, ipsilateral or bilateral sinuses.
Exclusion criteria
* Inability of caregiver to read and understand English * Mental retardation, cognitive impairment, or developmental delay * History of cystic fibrosis * History of immotile cilia syndrome * History of immune suppression/immune compromise * CT scan within past 4 weeks available for review at time of clinic visit which is entirely negative for evidence of sinus disease plus complete absence of any of the above symptoms * History of endoscopic sinus surgery * History of patient's inability to tolerate attempted nasal irrigation in the past 6 months * History of recent use of gentamycin intranasal irrigation or saline irrigation within the past 3 months * History of presence of nasal polyposis * History of allergic reaction of any kind to intravenous gentamycin or aminoglycosides in past medical history (for treatment of any infections)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Computed Tomography (CT) Score After Treatment | Change from Baseline to 6 Weeks | Change in CT score reflects the Lund-Mackay staging system. Each sinus is scored separately and scores are determined for the right and the left side. The lowest score of 0 represents no opacification in the sinus. A score of 1 represents a partial opacification. A score of 2 represents complete opacification. |
| Change in Overall Quality of Life | 3 Weeks to Follow-Up (7 Weeks) | Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Overall Quality of Life | Baseline to 3 Weeks | Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Saline Plus Gentamycin (Once Daily, 40 mL to Each Nostril) | 21 |
| Saline (Once Daily, 40 mL to Each Nostril) | 19 |
| Total | 40 |
Baseline characteristics
| Characteristic | Saline Plus Gentamycin (Once Daily, 40 mL to Each Nostril) | Saline (Once Daily, 40 mL to Each Nostril) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 21 Participants | 19 Participants | 40 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) White | 17 Participants | 18 Participants | 35 Participants |
| Region of Enrollment United States | 21 participants | 19 participants | 40 participants |
| Sex: Female, Male Female | 12 Participants | 3 Participants | 15 Participants |
| Sex: Female, Male Male | 9 Participants | 16 Participants | 25 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 3 / 21 | 6 / 19 |
| serious Total, serious adverse events | 0 / 21 | 0 / 19 |
Outcome results
Change in Computed Tomography (CT) Score After Treatment
Change in CT score reflects the Lund-Mackay staging system. Each sinus is scored separately and scores are determined for the right and the left side. The lowest score of 0 represents no opacification in the sinus. A score of 1 represents a partial opacification. A score of 2 represents complete opacification.
Time frame: Change from Baseline to 6 Weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left maxillary | -.64 units on a scale | Standard Deviation 0.63 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right maxillary | -.5 units on a scale | Standard Deviation 0.65 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left anterior ethmoid | -.79 units on a scale | Standard Deviation 0.7 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right anterior ethmoid | -.79 units on a scale | Standard Deviation 0.8 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left posterior ethmoid | -.57 units on a scale | Standard Deviation 0.65 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right posterior ethmoid | -.64 units on a scale | Standard Deviation 0.63 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left sphenoid | -.43 units on a scale | Standard Deviation 0.65 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right sphenoid | -.5 units on a scale | Standard Deviation 0.65 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left frontal | -.89 units on a scale | Standard Deviation 0.78 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right frontal | -.8 units on a scale | Standard Deviation 0.63 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left OMC | -1 units on a scale | Standard Deviation 1.03 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right OMC | -.86 units on a scale | Standard Deviation 1.29 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Total Score, left | -4.07 units on a scale | Standard Deviation 3.25 |
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Total score, right | -3.86 units on a scale | Standard Deviation 3.11 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left OMC | -1.25 units on a scale | Standard Deviation 1 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left maxillary | -.63 units on a scale | Standard Deviation 0.5 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right sphenoid | -.5 units on a scale | Standard Deviation 0.73 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right maxillary | -.5 units on a scale | Standard Deviation 0.63 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Total Score, left | -4.56 units on a scale | Standard Deviation 2.42 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left anterior ethmoid | -1.06 units on a scale | Standard Deviation 0.68 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left frontal | -.56 units on a scale | Standard Deviation 0.53 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right anterior ethmoid | -.63 units on a scale | Standard Deviation 0.81 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right OMC | -.88 units on a scale | Standard Deviation 1.02 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left posterior ethmoid | -.81 units on a scale | Standard Deviation 0.66 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right frontal | -.22 units on a scale | Standard Deviation 0.44 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Right posterior ethmoid | -.75 units on a scale | Standard Deviation 0.68 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Total score, right | -3.38 units on a scale | Standard Deviation 2.66 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Computed Tomography (CT) Score After Treatment | Left sphenoid | -.5 units on a scale | Standard Deviation 0.73 |
Change in Overall Quality of Life
Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.
Time frame: 3 Weeks to Follow-Up (7 Weeks)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Overall Quality of Life | .69 units on a scale | Standard Deviation 1.75 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Overall Quality of Life | 1.38 units on a scale | Standard Deviation 1.75 |
Change in Overall Quality of Life
Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.
Time frame: Baseline to 3 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Saline (Once Daily, 40 mL to Each Nostril) | Change in Overall Quality of Life | 2.53 units on a scale | Standard Deviation 1.99 |
| Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril) | Change in Overall Quality of Life | 2.06 units on a scale | Standard Deviation 2.88 |